
Search "anti-aging peptides" today and you will run into a few names over and over: Epitalon, MOTS-c, and a molecule called NAD+. They get sold together as a longevity stack, a combo meant to slow the clock. The science is a lot earlier, and a lot thinner, than the marketing suggests. Here is a calm, plain look at what these are and what the evidence actually shows.
Epitalon is a tiny lab-made peptide, just four building blocks long, based on a natural substance from the pineal gland. The pineal gland is a small gland in the brain that helps run your sleep clock. The peptide was developed decades ago by a Russian researcher named Vladimir Khavinson.
The big claim is about telomeres. Telomeres are like the plastic tips on shoelaces, except they sit on the ends of your DNA. They cap your chromosomes and get a little shorter each time a cell divides. When they get too short, the cell stops working well. Epitalon is said to switch on an enzyme called telomerase that can rebuild those caps. In lab dishes and in animals, it appears to do this, and it also seems to boost the body's natural antioxidant defenses and support melatonin, the hormone that helps you sleep.
In rodents, those effects added up to longer lives, with studies reporting lifespans 12 to 24 percent longer than untreated animals. That is genuinely interesting. But it is also where the honesty has to kick in.
Most of the strong results come from animals. The human studies are small and few, and a lot of the research comes from a single group in Russia, with little independent testing anywhere else. There are no large, careful trials of the kind regulators expect, and there is no long-term safety data in people. Epitalon is not an approved medicine. So the rodent lifespan numbers, exciting as they are, have not been shown to carry over to humans.
MOTS-c is a peptide tied to the mitochondria, the tiny power plants inside your cells. Early research, again mostly in animals, looks at whether it can help with metabolism and exercise. NAD+ is not a peptide at all. It is a helper molecule your cells use to make energy, and its levels drop as you age, which is why it gets bundled into longevity routines. Both sit at the same early stage as Epitalon: interesting ideas, promising lab work, and not much proof in people.
There is a timing reason this peptide is in the news. In late July 2026, an FDA advisory panel is set to review a short list of peptides, including Epitalon, to decide whether pharmacies should be allowed to prepare them. The specific question on Epitalon is about using it for insomnia, not for living longer. We explained how that review works in our piece on the FDA peptide compounding changes. Whatever the panel decides, it will not settle the bigger anti-aging claims, which still need real human trials.
Longevity peptides sit in a tricky spot. The biology is real and the animal results are eye-catching, but the leap from a longer-lived mouse to a longer-lived person is a huge one that has not been made. If you see Epitalon or a longevity stack sold with promises about turning back your age, treat the promise as marketing, not settled science. The honest summary is short: early, hopeful, and unproven in people.
Written by
Dr. Anna Chereshnevskyi
General Practitioner
Dr. Chereshnevskyi is a general practitioner who graduated from Lviv National Medical University and currently practices at a state hospital in Ankara, Turkey. She specialises in primary care and follows the clinical literature on peptide therapies, metabolic health, and longevity research. She contributes to Peptide.pub as a medical reviewer and blog author, translating complex research into plain, evidence-based language.
About Peptide.pub →